U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H27N3O2.2ClH
Molecular Weight 402.358
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BAVISANT DIHYDROCHLORIDE ANHYDROUS

SMILES

Cl.Cl.O=C(N1CCN(CC1)C2CC2)C3=CC=C(CN4CCOCC4)C=C3

InChI

InChIKey=PBVFXCXXVLBYKF-UHFFFAOYSA-N
InChI=1S/C19H27N3O2.2ClH/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20;;/h1-4,18H,5-15H2;2*1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H27N3O2
Molecular Weight 329.4366
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Bavisant (also known as JNJ-31001074 or BEN-2001), a highly selective, active antagonist of the human H3 receptor that was invented by Johnson & Johnson for the treatment of attention-deficit hyperactivity disorder (ADHD). However, the result of clinical trials did not display significant clinical effectiveness in the treatment of adults with ADHD. BenevolentAI has started phase II clinical trials where investigated bavisant for ameliorating the excessive daytime sleepiness in patients with Parkinson’s disease, using one of the drug side effects is dose-dependent insomnia.

Approval Year

PubMed

PubMed

TitleDatePubMed
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
2011 Jul 14
Patents

Sample Use Guides

Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or osmotic-release oral system (OROS) methylphenidate hydrochloride 54 mg/day.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Thu Jul 06 02:24:16 UTC 2023
Edited
by admin
on Thu Jul 06 02:24:16 UTC 2023
Record UNII
1B5560RN9F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BAVISANT DIHYDROCHLORIDE ANHYDROUS
Common Name English
METHANONE, (4-CYCLOPROPYL-1-PIPERAZINYL)(4-(4-MORPHOLINYLMETHYL)PHENYL)-, HYDROCHLORIDE (1:2)
Systematic Name English
(4-CYCLOPROPYLPIPERAZIN-1-YL)(4-(MORPHOLIN-4-YLMETHYL)PHENYL)METHANONE DIHYDROCHLORIDE
Systematic Name English
Bavisant dihydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
CAS
929622-09-3
Created by admin on Thu Jul 06 02:24:16 UTC 2023 , Edited by admin on Thu Jul 06 02:24:16 UTC 2023
PRIMARY
SMS_ID
300000042549
Created by admin on Thu Jul 06 02:24:16 UTC 2023 , Edited by admin on Thu Jul 06 02:24:16 UTC 2023
PRIMARY
FDA UNII
1B5560RN9F
Created by admin on Thu Jul 06 02:24:16 UTC 2023 , Edited by admin on Thu Jul 06 02:24:16 UTC 2023
PRIMARY
PUBCHEM
66712477
Created by admin on Thu Jul 06 02:24:16 UTC 2023 , Edited by admin on Thu Jul 06 02:24:16 UTC 2023
PRIMARY
EPA CompTox
DTXSID00239212
Created by admin on Thu Jul 06 02:24:16 UTC 2023 , Edited by admin on Thu Jul 06 02:24:16 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS